These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

83 related items for PubMed ID: 8331927

  • 1. IL-1 receptor antagonist (IL-1ra) augments IL-2-induced pulmonary vascular leak.
    Thom AK, Fraker DL, Norton JA.
    J Surg Res; 1993 Apr; 54(4):336-41. PubMed ID: 8331927
    [Abstract] [Full Text] [Related]

  • 2. Interleukin-1 receptor antagonist inhibits subcutaneous B16 melanoma growth in vivo.
    McKenzie RC, Oran A, Dinarello CA, Sauder DN.
    Anticancer Res; 1996 Apr; 16(1):437-41. PubMed ID: 8615650
    [Abstract] [Full Text] [Related]

  • 3. Decrease in interleukin 2-induced vascular leakage in the lungs of mice by administration of recombinant interleukin 1 alpha in vivo.
    Puri RK, Travis WD, Rosenberg SA.
    Cancer Res; 1989 Feb 15; 49(4):969-76. PubMed ID: 2783561
    [Abstract] [Full Text] [Related]

  • 4. Attenuation of interleukin 2-induced pulmonary vascular leak syndrome by low doses of oral methotrexate.
    DeJoy SQ, Jeyaseelan R, Torley LW, Schow SR, Wick MM, Kerwar SS.
    Cancer Res; 1995 Nov 01; 55(21):4929-35. PubMed ID: 7585532
    [Abstract] [Full Text] [Related]

  • 5. Histamine improves survival and protects against interleukin-2-induced pulmonary vascular leak syndrome in mice.
    Hornyak SC, Orentas DM, Karavodin LM, Gehlsen KR.
    Vascul Pharmacol; 2005 Mar 01; 42(4):187-93. PubMed ID: 15820445
    [Abstract] [Full Text] [Related]

  • 6. Inducible nitric oxide synthase (iNOS) is not required for IL-2-induced hypotension and vascular leak syndrome in mice.
    Kondapaneni M, McGregor JR, Salvemini D, Laubach VE, Samlowski WE.
    J Immunother; 2008 May 01; 31(4):325-33. PubMed ID: 18391763
    [Abstract] [Full Text] [Related]

  • 7. Mouse IL-1 receptor antagonist isoforms: complementary DNA cloning and protein expression of intracellular isoform and tissue distribution of secreted and intracellular IL-1 receptor antagonist in vivo.
    Gabay C, Porter B, Fantuzzi G, Arend WP.
    J Immunol; 1997 Dec 15; 159(12):5905-13. PubMed ID: 9550387
    [Abstract] [Full Text] [Related]

  • 8. Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist.
    Smeets RL, Joosten LA, Arntz OJ, Bennink MB, Takahashi N, Carlsen H, Martin MU, van den Berg WB, van de Loo FA.
    Arthritis Rheum; 2005 Jul 15; 52(7):2202-11. PubMed ID: 15986350
    [Abstract] [Full Text] [Related]

  • 9. Increased production of intracellular interleukin-1 receptor antagonist type I in the synovium of mice with collagen-induced arthritis: a possible role in the resolution of arthritis.
    Gabay C, Marinova-Mutafchieva L, Williams RO, Gigley JP, Butler DM, Feldmann M, Arend WP.
    Arthritis Rheum; 2001 Feb 15; 44(2):451-62. PubMed ID: 11229477
    [Abstract] [Full Text] [Related]

  • 10. Interleukin-1 receptor blockade reduces the number and size of murine B16 melanoma hepatic metastases.
    Vidal-Vanaclocha F, Amézaga C, Asumendi A, Kaplanski G, Dinarello CA.
    Cancer Res; 1994 May 15; 54(10):2667-72. PubMed ID: 8168095
    [Abstract] [Full Text] [Related]

  • 11. Induction of interleukin 1 receptor antagonist after interleukin 1 therapy in patients with cancer.
    Kopp WC, Urba WJ, Rager HC, Alvord WG, Oppenheim JJ, Smith JW, Longo DL.
    Clin Cancer Res; 1996 Mar 15; 2(3):501-6. PubMed ID: 9816196
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Inhibition by interleukin 1 receptor antagonist of in vivo activities of interleukin 1 in mice.
    Mengozzi M, Bertini R, Sironi M, Ghezzi P.
    Lymphokine Cytokine Res; 1991 Oct 15; 10(5):405-7. PubMed ID: 1837482
    [Abstract] [Full Text] [Related]

  • 18. Effect of stimulation and antagonism of interleukin-1 signaling on preterm delivery in mice.
    Yoshimura K, Hirsch E.
    J Soc Gynecol Investig; 2005 Oct 15; 12(7):533-8. PubMed ID: 16202930
    [Abstract] [Full Text] [Related]

  • 19. Altered expression of interleukin-1 receptor antagonist in different stages of mouse skin carcinogenesis.
    La E, Muga SJ, Locniskar MF, Fischer SM.
    Mol Carcinog; 1999 Apr 15; 24(4):276-86. PubMed ID: 10326864
    [Abstract] [Full Text] [Related]

  • 20. Cutaneous mast cell degranulation in rats receiving injections of recombinant human interleukin-1 receptor antagonist (rhIL-1ra) and/or its vehicle: possible clinical implications.
    Bendele A, Colloton M, Vrkljan M, Morris J, Sabados K.
    J Lab Clin Med; 1995 Apr 15; 125(4):493-500. PubMed ID: 7706905
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.